Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SillaJen Inc.

www.sillajen.com

Latest From SillaJen Inc.

Genexine, ToolGen Merger Collapses Amid Stock Drops, But Collaboration Still Planned

The planned merger between Genexine and ToolGen, which was poised to create a major Korean biotech entity, has collapsed amid recent generally weak investor sentiment over the sector. But the two sides will maintain their collaborations for new drug development going forward, with a focus on gene and cell therapies.

South Korea M & A

Inovio Eyes Expanded Asian Opportunities, Presence Via Korea Dual Listing

Inovio is poised to become the first US-listed company to dual-list in South Korea, as CEO tells Scrip it is seeking to increase its presence and find new opportunities in Asia, while benefiting from strong investor interest in the country’s "very exciting" and vibrant biotech industry.

South Korea Financing

Transgene Downplays Impact Of Pexa-Vec Phase III Cancer Trial Failure

A late-phase assessment of the oncolytic virus in liver cancer patients was stopped early for futility but Transgene thinks the failure is an isolated event.

Clinical Trials Research & Development

AZ Targets Viral Oncolytics With Transgene Development Deal

AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.

Research & Development Deals
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • SillaJen Co. Ltd.
  • SillaJen Biotherapeutics
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • SillaJen Inc.
  • Senior Management
  • Eun-Sang Moon, CEO
  • Contact Info
  • SillaJen Inc.
    Phone: 51 510 7550
    6F, 252, Geumjeong-ro
    Geumjeong-gu
    Busan, 46274
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register